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Abstract 
Background: Anti‑malarial drug resistance is a primary public health problem. Haplotypes of pfcrt gene have been 
implicated to be molecular markers of chloroquine (CQ) resistance. This study aims to explore the prevalence of poly‑
morphisms in pfcrt in Plasmodium falciparum‑infected patients imported from Africa in Henan province.
Methods: Blood samples were collected from 502 patients who were infected with P. falciparum returning from 
Africa in Henan province during 2012–2015. The single nucleotide polymorphisms in pfcrt (codons 72–76) were 
assessed by nested PCR with DNA sequencing and restriction digestion, the haplotype prevalences were also 
determined.
Results: Four haplotypes coding 72–76 of pfcrt were found including CVMNK (wild type), CVIET (mutation type), 
CVIEK (mutation type), and CV M/I N/E/D/K K/T (mixed type), with 61.95 % (311/502), 33.07 % (166/502), 0.20 % 
(1/502), and 4.78 % (24/502) prevalence, respectively. Except mixed type, CVIET and CVIEK were the largest proportion 
of the mutant type in West Africa, accounting for 44.83 % (91/203), followed by East Africa (8/21, 38.10 %), North Africa 
(4/11, 36.36 %), Central Africa (36/135, 26.67 %), and South Africa (28/132, 21.21 %). There was significant difference 
among the groups (χ2 = 23.78, P < 0.05). Mixed type was the largest proportion in North Africa (9.09 %), followed by 
Central Africa (6.67 %), East Africa (4.76 %), South Africa (4.55 %), and West Africa (3.45 %). There was no significant 
difference among the groups (χ2 = 2.31, P > 0.05). The position 72 and 73 of pfcrt showed predominance for the wild 
type with rates of 100 % (502/502).
Conclusions: This study identified four haplotypes of pfcrt in P. falciparum‑infected patients imported from Africa in 
Henan province. The prevalence of mutations in the pfcrt was dropped comparing with other people’s researches. It 
establishes fundamental data for detection of P. falciparum CQR with molecular markers for the imported P. falciparum 
in China, and it also provides complementary information of CQR for the malaria endemic countries and assesses the 
evolution of anti‑malarial drug resistance.
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Background
Malaria is an infectious disease that has been present in 
sub-tropical and temperate countries for much of his-
tory. It varies widely in epidemiology and clinical mani-
festation and is responsible for an estimated 214 million 
clinical episodes and approximately 438,000 deaths per 
year, of which approximately 90 % occur in Africa [1]. In 
2010, the Ministry of Health in China launched an ‘action 
plan for malaria elimination’, with the goals of eliminating 
malaria in the entire country by the end of 2020 [2]. There 
has been no indigenous malaria case in Henan province 
since 2012, whereas the imported cases have increased 
year-by-year, most of which were imported Plasmodium 
falciparum from Africa [3–6].
The variability in the spectrum of malarial diseases is 
the result of several factors, including the distribution 
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of the two primary species of malaria parasites (P. fal-
ciparum and P. vivax), their levels of susceptibility to 
anti-malarial drugs, the distribution and efficiency of 
mosquito vectors, climate and other environmental con-
ditions and the behaviour and level of acquired immunity 
of the exposed human populations [7]. Due to the lack 
of an effective vaccine, malaria is currently re-infectious 
and thus its case management depends solely on anti-
malarials [8, 9]. Efficacious anti-malarial medicines are 
critical to malaria control, and continuous monitoring 
of their efficacy is needed to inform treatment policies in 
malaria-endemic countries, and to ensure early detection 
of, and response to, drug resistance [10].
Chloroquine (CQ) was used to combat malaria in 1940s 
after the Second World War. Since then, it has been con-
sidered to be the drug of choice for the treatment of non-
severe, uncomplicated malaria and for chemoprophylaxis 
[11]. Over the years, CQ has proven to be one of the most 
successful and important drugs ever deployed against 
malaria, especially in the highly endemic areas of Africa 
[12]. The tremendous success of CQ and its heavy use 
for almost 12 years [13] led to the development of resist-
ance in P. falciparum during the late 1950s [14–18]. CQ 
resistance (CQR) was reported for the first time at the 
Thailand-Cambodia border in 1957 and the Venezuela-
Colombia border in 1959 and eventually spread to other 
countries throughout the world [19–21]. Soon after, 
CQR P. falciparum isolates were found to be widespread 
in malaria-endemic zones, the mutagenic basis of CQR 
was made evident by several clinical and epidemiological 
studies [22, 23]. Amino acid polymorphisms have been 
found in exon 2 of the pfcrt gene at residues 72, 74, 75 and 
76 in P. falciparum isolates, suggesting that they may be 
involved in the genetic characterization of CQR and CQ 
sensitivity (CQS). Accordingly, whereas the C72 V73M74 
N75 K76 haplotype is considered to be CQS, parasites with 
polymorphisms at any of these amino acid positions are 
considered to be CQR [24, 25]. In this study, the preva-
lence of polymorphisms in pfcrt gene were determined 
from imported P. falciparum patients in Henan province 
who came back from Africa.
Methods
Sample collection and DNA extraction
Blood samples were collected from patients with P. fal-
ciparum infection prior to treatment. All of the patients 
came from Africa in year 2012–2015. The final diagnosis 
was made by microscopic examination of Giemsa-stained 
thick blood films and nested PCR. For each sample, 
approximately 200  μl of finger-prick blood was spot-
ted on a piece of Whatman 3 M 903 filter paper and air-
dried. The dried filters were stored in individual plastic 
bags at −20 °C until DNA extraction. Parasite DNA was 
extracted from the blood filters using a QIAamp DNA 
mini kit (Qiagen, Valencia, CA, USA) following the man-
ufacturer’s instruction.
Nested PCR amplification and DNA sequencing
Nested PCR [26–28] was performed to amplify the frag-
ments of pfcrt using a DNA thermal cycler (Mastercycler 
nexus, Eppendorf Ltd, Germany). The primary PCR was 
performed in a 20-μl reaction volume containing 6.0  μl 
ddH2O, 1.0  μl each of OuterP1, and OuterP2 primers 
(10 μmol/l), 10 μl 2 × Go Taq Green Master Mix (Pro-
mega, USA) and 2.0 μl DNA template. The PCR reaction 
condition was 94 °C for 3 min; 35 cycles of 94 °C for 30 s, 
56 °C for 30 s, and 60 °C for 60 s; and a final extension at 
60 °C for 5 min. The nested PCR contained 7.0 μl ddH2O, 
1.0 μl each of InnerP1, and InnerP2 primers (10 μmol/l), 
10 μl 2 × Go Taq Green Master Mix, 1.0 μl from the first 
PCR product. The PCR reaction condition was the fol-
lowing: 94 °C for 3 min; 35 cycles of 94 °C for 30 s, 48 °C 
for 30 s, and 65 °C for 60 s; and a final extension at 65 °C 
for 5 min. The amplified products were purified from an 
agarose gel and sequenced by Sangon Biotech Co Ltd 
(Shanghai, China). Primers were also synthesized by San-
gon Biotech Co Ltd. Primer sequences are provided in 
Table 1.
Restriction digest of pfcrt gene amplicons
Enzymatic digestion of the resulting 145 base pair frag-
ment of the pfcrt amplicons was done using Apo I restric-
tion enzyme (Fermentas Life Sciences) according to the 
manufacturer’s instructions.
Sequencing alignments and data analysis
Sequence alignments and analysis were carried out 
using BioEdit software. Amino acid sequences were 
compared with 3D7 strain, which was obtained from 
the Chinese Centre for Disease Control and Prevention. 
The sequences of the amplicons were aligned with 3D7 
strain published data from the NCBI database by BLAST 
analysis. All the data were proceed using Excel to build 
Table 1 PCR primer sequences used for  the amplification 
sequence encoding pfcrt
Gene Primer Sequence (5′–3′) Size (bp)
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database and the SPSS 17.0 software was used for analy-
sis. The Person’s Chi square test was used to determine 
significance of results. A P value  <0.05 was considered 
statistically significant.
Ethical approval
The study was reviewed and approved by the Project of 
Medical Science and Technology of Henan province (No. 
201304053). Before sampling, the purpose was illustrated 
to participants and consent was obtained from those who 
agreed to participate in the survey.
Results
General characteristics of patients
Blood samples were collected from 502 patients who 
were infected with P. falciparum returning from 26 coun-
tries of Africa to Henan province during 2012–2015. The 
male:female ratio was 70.71:1 (495/7). The mean age was 
38.07 ± 9.31 years (range 17–70 years old), of which only 
2 patients were older than 60 years and one patient was 
under 18 years; 502 patients were returned from 26 coun-
tries in Africa, the majority (40.44 %, 203) of whom were 
from West Africa, followed by Central Africa (26.89  %, 
135) and South Africa (26.29 %, 132). The minority were 
returned from East Africa and North Africa, accounting 
for 4.18 % (21) and 2.19 % (11), respectively.
PCR–RFLP of the pfcrt gene
The nested PCR yielded a 145-bp PCR product for each 
of the 502 samples. These products contained the codons 
of interest, 72 through 76, which were analysed both by 
enzymatic digestion and sequencing. The resulting of 
Apo I enzymatic digestion yielded two fragments of 31 
and 114 bp in the case of the parasite strains containing 
the wild K76 variant, whereas the mutant T76 variant 
yielded only one fragment since there was no digestion. 
Multi-clonal variants yielded three fragments (145, 114 
and 31-bp products). A photo of agarose gel electro-
phoresis is shown in Fig. 1. Restriction digest of the 502 
samples gave the following results: 166 (33.07 %) mutant 
types, 312 (62.15  %) wild types and 24 (4.78  %) mixed 
infections, which were also confirmed by sequencing (see 
Fig. 2).
Pfcrt mutations and haplotypes
A 145-bp fragment of the pfcrt gene, including residues 
72–76, was successfully sequenced from all the samples. 
The position 72 and 73 of pfcrt were all the wild type with 
rates of 100 % (502/502). Four haplotypes coding 72–76 
of pfcrt were found, including CVMNK (wild type), 
CVIET (mutation type), CVIEK (mutation type), and CV 
M/I N/E/D/K K/T (mixed type), with 61.95 % (311/502), 
33.07  % (166/502), 0.20  % (1/502) and 4.78  % (24/502) 
prevalence, respectively. The detail information and 
sequencing results of the mutations are shown in Fig. 2 
and Table 2, respectively.
Distribution of the CQR‑pfcrt haplotypes
Four haplotypes coding 72–76 of pfcrt were found; only 
one patient harboured the CVIEK, who was returned 
from Nigeria in West Africa. The other three haplo-
types were found in the every region of Africa; 203 iso-
lates returned from ten countries in West Africa carried 
four haplotypes: CVMNK, CVIET, CVIEK and CV M/I 
N/E/D/K K/T, with 51.72 % (105/203), 44.33 % (90/203), 
0.49  % (1/203) and 3.45  % (7/203) prevalence, respec-
tively. 135 isolates returned from six countries in Cen-
tral Africa carried three haplotypes: CVMNK, CVIET 
and CV M/I N/E/D/K  K/T, with 66.67  % (90/135), 
26.67 % (36/136) and 6.67 % (9/135) prevalence, respec-
tively. A total of 132 isolates returned from four coun-
tries in South Africa carried three haplotypes: CVMNK, 
CVIET and CV M/I N/E/D/K K/T, with 74.24 % (98/132), 
21.21 % (28/132) and 4.55 % (6/132) prevalence, respec-
tively. Twenty-one isolates returned from four countries 
in East Africa carried three haplotypes: CVMNK, CVIET 
and CV M/I N/E/D/K K/T, with 57.14 % (12/21), 38.10 % 
(8/21) and 4.76 % (1/21) prevalence, respectively. Eleven 
isolates returned from two countries in North Africa 
carried three haplotypes: CVMNK, CVIET and CV M/I 
N/E/D/K  K/T, with 54.55  % (6/11), 36.36  % (4/11) and 
9.09 % (1/11) prevalence, respectively. Except mixed type, 
CVIET and was the largest proportion of the mutant 
type in West Africa, accounting for 44.33 % (90/203), fol-
lowed by East Africa (8/21, 38.10 %), North Africa (4/11, 
Fig. 1 Identification of the four haplotypes by enzyme digestion. 
Lanes 1, 3, 5 and 7 were the nested PCR product of the four haplo‑
types. Lanes 2, 4, 6 and 8 were digested by Apo I. M, molecular marker; 
lanes 1 and 2, CVMNK; lanes 3 and 4, CVM/I N/E/D/K T/K; lanes 5 and 6, 
CVIET; lanes 7 and 8, CVIEK
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36.36  %), Central Africa (36/135, 26.67  %) and South 
Africa (28/132, 21.21  %). There was significant differ-
ence among the groups (χ2 = 23.78, P < 0.05). There was 
the largest proportion of the mixed type in North Africa 
(9.09 %), followed by Central Africa (6.67 %), East Africa 
(4.76 %), South Africa (4.55 %) and West Africa (3.45 %). 
There was no significant difference among the groups 
(χ2 = 2.31, P > 0.05) (see Table 2).
Discussion
Information on the distribution and patterns of anti-
malarial drug resistance is essential for implementation 
of effective malaria control programmes and disease 
surveillance in all malaria-endemic areas of the world. 
Early detection of occurrence and spreading of anti-
malarial drug resistance would be greatly enhanced by 
the application of valid anti-malarial resistance molecu-
lar markers. CQ has been used widely in African regions 
for several decades and formed a strong selection 
pressure on parasite populations. The World Health 
Organization advocated a complete ban on artemisinin 
monotherapy for uncomplicated malaria in 2006 [29]. 
The national drug policy of China was updated in 2009, 
and first-line drugs currently used to treat falciparum 
malaria are ACT, which includes dihydroartemisinin-
piperaquine (DHA-PIP), artesunate+amodiaquine, 
artemisinin-naphthoquine phosphate and artemisinin-
piperaquine [30]. Among the candidate genes investi-
gated to date, pfcrt mutation is widely acceptable as a 
reliable marker of CQR in P. falciparum in epidemiolog-
ical studies [23, 31]. So it is important to understand the 
molecular mutation profiles of P. falciparum parasite for 
anti-malarial drug resistance and use this foundational 
information for detection of molecular pattern.
For CQR P. falciparum, two principal haplotypes, with 
the amino acid sequences C72 V73 I74 E75 T76 and S72 
V73 M74 N75 T76 [24, 25] are widely distributed. Due to 
the widespread yet structured present-day distribution 
across P. falciparum-endemic zones across the globe, 
these two haplotypes are hypothetically considered to be 
CQR mother haplotypes and the other minor haplotypes 
are believed to have been derived from them [24, 25]. It 
has been established that CVIET and SVMNT are widely 
prevalent; whether all of the other minor haplotypes were 
derived from these two or evolved independently is still 
an open question.
Mutations in pfcrt are connected to resistance of anti-
malarial medication, including CQ, amodiaquine (AQ) 
and lumefantrine (LU), and the haplotypes of pfcrt 
CVIET and SVMNT have been implicated [32]. The 
pfcrt CQR haplotypic view in Africa is completely biased 
towards the CVIET haplotype, owing to the wide usage 
Fig. 2 Sequencing profile of nested PCR product of pfcrt genotypes detected in Plasmodium falciparum isolates imported from Africa in Henan 
province. a The wild type. The haplotype named CVMNK was got from 3D7. b and c The mutation. The haplotype was named CVIET and CVIEK, 
respectively. d The mixed type. The position was showed by degenerate base. The haplotype was named CVM/I N/E/D/K T/K. The mutation position 
is indicated by the arrow
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of CQ and AQ drugs in many African countries [33]. 
This study indicated 33.07 % isolates harboured the pfcrt 
mutant CVIET, while 4.98  % isolates had the CVIET-
derived haplotypes, CV M/I N/E/D/K K/T (4.78 %) and 
CVIEK (0.20  %). The two main methods, namely Apo I 
enzymatic digestion and the sequencing, employed here 
to analyse the pfcrt gene status of the parasite strains 
from the study participants served to confirm or com-
plement findings from each of the methods. There was 
no SVMNT haplotype found in isolates returned from 
Africa in this study. The pfcrt SVMNT is more com-
monly found in South America and some Asian countries 
[34], but rarely reported from the African continent. The 
result in this study that no SVMNT haplotype found in 
isolates returned from Africa confirm the above conclu-
sion. Except mixed type, there was the largest proportion 
of the mutant type in West Africa, accounting for 44.83 % 
(CVIET and CVIEK, 91/203); this difference might 
come from the amount of AQ used in different regions. 
In this study, 4.78  % mixed type (wild type and mutant 
type) of pfcrt was detected in falciparum malaria iso-
lates returned from ten countries (Angola, Equatorial 
Guinea, Cameroon, Nigeria, Sierra Leone, The Republic 
of Guinea, Ghana, Mali, Libya, Tanzania). It was reported 
that 6.62 % mixed type of pfcrt was found in malaria iso-
lates from Bioko Island, Equatorial Guinea [35], which 
was not reported in neighbouring countries [36–39]. 
This study enriched the distribution of the mixed type of 
pfcrt. The CVIEK haplotype was reported to be detected 
in Central Africa Republic, Gabon, Sudan, Thailand, and 
Eastern India [40–46]. In this study, among 502 isolates, 
only one patient harboured the CVIEK haplotype, who 
Table 2 Distribution of the CQR-pfcrt haplotypes from Africa-imported cases
a There was only one P. falciparum isolate from Nigeria with CVIEK haplotype
Region Country Total CVMNK CVIET CV M/I N/E/D/K K/T
North Africa 11 6 (54.55 %) 4 (36.36 %) 1 (9.09 %)
Sudan 9 6 (66.67 %) 3 (33.33 %) 0 (0.00 %)
Libya 2 0 (0.00 %) 1 (50.00 %) 1 (50.00 %)
East Africa 21 12 (57.14 %) 8 (38.10 %) 1 (4.76 %)
Ethiopia 2 0 (0.00 %) 2 (100 %) 0 (0.00 %)
Kenya 3 3 (100 %) 0 (0.00 %) 0 (0.00 %)
Tanzania 10 6 (60.00 %) 3 (30.00 %) 1 (10.00 %)
Uganda 6 3 (50.00 %) 3 (50.00 %) 0 (0.00 %)
South Africa 132 98 (74.24 %) 28 (21.21 %) 6 (4.55 %)
Angola 101 69 (68.32 %) 26 (25.74 %) 6 (5.94 %)
Zimbabwe 1 1 (100 %) 0 (0.00 %) 0 (0.00 %)
Mozambique 10 9 (90.00 %) 1 (10.00 %) 0 (0.00 %)
Zambia 20 19 (95.00 %) 1 (5.00 %) 0 (0.00 %)
West Africa 203 (202 + 1a) 105 (51.72 %) 90 (44.33 %) 7 (3.45 %)
Benin 5 1 (20.00 %) 4 (80.00 %) 0 (0.00 %)
Togo 5 4 (80.00 %) 1 (20.00 %) 0 (0.00 %)
The Republic of Guinea 33 21 (63.64 %) 11 (33.33 %) 1 (3.03 %)
Ghana 23 19 (82.61 %) 3 (13.04 %) 1 (4.35 %)
Ivory Coas 10 7 (70.00 %) 3 (30.00 %) 0 (0.00 %)
Liberia 23 1 (4.35 %) 22 (95.65 %) 0 (0.00 %)
Mali 4 2 (50.00 %) 1 (25.00 %) 1 (25.00 %)
Nigeria 74 (73 + 1a) 40 (54.05 %) 31 (41.89 %) 2 (2.7 %)
Sierra Leone 25 9 (36.00 %) 14 (56.00 %) 2 (8.00 %)
Burkina Faso 1 1 (100 %) 0 (0.00 %) 0 (0.00 %)
Central Africa 135 90 (66.67 %) 36 (26.67 %) 9 (6.67 %)
Equatorial Guinea 75 58 (77.33 %) 11 (14.67 %) 6 (8.00 %)
Congo 23 11 (47.83 %) 12 (52.17 %) 0 (0.00 %)
Gabon 6 1 (16.67 %) 5 (83.33 %) 0 (0.00 %)
Cameroon 23 14 (60.87 %) 6 (26.09 %) 3 (13.04 %)
Chad 7 5 (71.43 %) 2 (28.57 %) 0 (0.00 %)
Central Africa Republic 1 1 (100 %) 0 (0.00 %) 0 (0.00 %)
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returned from Nigeria. It was the first report that CVIEK 
haplotype found in West Africa.
Five-hundred and two patients were returned from 26 
countries in Africa; half of them (250/502, 49.80 %) were 
from three countries: Angola (101), Equatorial Guinea 
(75) and Nigeria (74). The remainder returned from the 
other 23 countries, but there were 16 countries from 
which fewer than or equal to ten patients returned, so it 
was hard to fully explain the situation of the pfcrt in each 
country.
In regions with high malaria endemic, the withdrawal 
of CQ as first-line treatment of P. falciparum infections 
has typically led to the restoration of CQ susceptibility 
through the reexpansion of the wild type allele of pfcrt 
at the expense of less fit mutant alleles carrying the CQR 
marker. In French Guiana, despite the fixation of the 
K76T allele, the prevalence of CQR isolates progressively 
dropped from >90 % to <30 % during 17 years after CQ 
withdrawal in 1995 [47]. In this study, the prevalence of 
CVIET haplotype among 502 isolates was 33.07 %, which 
was consistent with the above results. Gharbi et al. recon-
firmed this conclusion, they carried out a longitudinal 
study assessing the return of chloroquine susceptibil-
ity of P. falciparum in isolates from travellers returning 
from West and Central Africa, during 2000–2011, the 
prevalence of the fcrt76T mutant genotype significantly 
decreased [48, 49].
Travelers who return from endemic countries infected 
with malaria often present with low immunity against the 
parasites and there is no risk of re-infection, so they are 
a particularly valuable source of information. Many set-
tings in endemic countries lack the financial resources 
necessary to maintain a sustainable, accurate and reliable 
anti-malarial resistance surveillance system, resulting in 
gaps in the spatial and temporal available information. 
This study can provide complementary information of 
CQR for the malaria endemic countries.
Conclusions
This study reports the prevalence of polymorphisms 
in pfcrt gene in blood sample obtained from P. falcipa-
rum-infected patients imported from Africa in Henan 
province, and it illustrates the situation of CQR for the 
patients of P. falciparum imported from Africa, which 
is essential for implementation of effective malaria 
elimination programmes and drug resistance surveil-
lance in Henan province. Continuous molecular sur-
veillance with pfcrt gene of imported P. falciparum as 
an anti-malarial drug resistance marker is exceedingly 
recommended in China. It will be useful for the malaria 
endemic countries to assess the evolution of anti-malar-
ial drug resistance and provide complementary informa-
tion of CQR.
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